Lumida
/NUVL
⌘K
Nuvalent Inc

Nuvalent Inc

NUVL
$123.96USD↑+0.00%+0.00 today

MARKET CAP

9.8B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$124 – $124

52W RANGE

$124
$124

AI Summary

Stalk
Sell NowHigh

NUVL is in a Stage 4 decline with sequential lower highs and lower lows and is trading below all major EMAs and moving averages. The active Support Failure and Lower Highs & Lower Lows patterns confirm supply dominance and ongoing downtrend. With no signs of stabilization, EMA repair, or volatility contraction, selling into rallies at the 9EMA/20EMA and 50DMA is the preferred execution posture now.

  • ↑PDUFA Nov 27 ’26 for neladalkib and Sep 18 ’26 for zidesamtinib could drive approvals
  • ↑Total addressable oncology market >$150 B supports high revenue potential
  • ↓Q2 EPS of -$6.06 and ROE -41% highlight severe losses
Full analysis →
Sales, Adj.
No data
Gross Profit, Adj.
No data
EBITDA, Adj.
EBIT
Net Income